Xeloda

(Capecitabine)

ApprovedSmall molecule

Capecitabine is used to treat certain types of cancer, including colorectal cancer and breast cancer. It works by slowing or stopping the growth of cancer cells in the body.[2] Xeloda is currently approved and in use across 118 indications[4].[1]

Xeloda is one of 1181 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Approved.

118

Indications

1,353

Total Trials

Active Trials

1,180

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Rectum CancerRecruiting

Gastroesophageal Junction AdenocarcinomaCompleted

Breast CancerCompleted

Colorectal CancerCompleted

Liver CancerTerminated

Biliary Tract CancerActive, not recruiting

Gastric NeoplasmsActive, not recruiting

Locally-Advanced Rectal CancerNot yet recruiting

Intestinal CancerCompleted

Triple-Negative Breast CancerPhase 3

Active, not recruiting

Rectum CancerPhase 3

Recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Completed

Breast CancerApproved

Completed

Colorectal CancerApproved

Completed

Liver CancerPhase 3

Terminated

Biliary Tract CancerPhase 3

Active, not recruiting

Gastric NeoplasmsPhase 3

Active, not recruiting

Locally-Advanced Rectal CancerPhase 3

Not yet recruiting

Intestinal CancerPhase 2

Completed

Showing 10 of 118 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Adenocard

2 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Lexiscan

Astellas

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

Acupan

YYonsei University

Preclinical

1 9

Duragesic

CCephalon

Preclinical

1 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Breast Cancer

NCT06568692

Phase 1/2Active, not recruiting

Breast Cancer

NCT03377387

Phase 2Not yet recruiting

Chemotherapy

NCT06788171

Phase 2Active, not recruiting

Gastric Cancer

NCT03257163

Phase 2Recruiting

Gastric Cancer

NCT03161522

Q2 2027

Phase 2Not yet recruiting

Nasopharyngeal Cancer

NCT06892431

Clinical

Trials by Indication[1]

Breast Cancer51 trials

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Recruiting·PProcessa Pharmaceuticals·Phase 2·NCT06568692·90 enrolled

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT03377387·34 enrolled

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02555657·622 enrolled

Show 48 more trials

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

Completed·—·Phase 1·NCT00153907·40 enrolled

Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine

Completed·UUniversity of Michigan Rogel Cancer Center·N/A·NCT00156312·25 enrolled

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Unknown status·GGenta Incorporated·Phase 2·NCT01609127·213 enrolled

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Completed·PPuma Biotechnology, Inc.·Phase 1/2·NCT00741260·105 enrolled

A Phase III Trial For Patients With Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191152·475 enrolled

GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00068588·24 enrolled

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

Terminated· Novartis logo

Novartis·Phase 3·NCT00508274·52 enrolled

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting·NNational Institute of Oncology, Hungary··NCT05131893·300 enrolled

Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer

Completed·IiOMEDICO AG·Phase 3·NCT00868634·600 enrolled

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

Recruiting·UUniversity of Southern California·Phase 1/2·NCT04333706·65 enrolled

Capecitabine in Low Risk Triple Negative Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06787339·198 enrolled

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Approved for marketing· Pfizer logo

Pfizer··NCT04220203

Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer

Completed·JJapan Breast Cancer Research Network·Phase 2·NCT00438100·142 enrolled

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00266799·210 enrolled

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

Terminated·MMerrimack Pharmaceuticals·Phase 2/3·NCT02213744·113 enrolled

Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer

Completed·TThomas Hatschek·Phase 3·NCT01433614·304 enrolled

A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)

Terminated·FFudan University·Phase 3·NCT01655992·386 enrolled

Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Completed·SSwiss Cancer Institute·Phase 1/2·NCT00031876·34 enrolled

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

Unknown status·JJinming Yu·Phase 2·NCT04095390·60 enrolled

Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT00049660·47 enrolled

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Completed·PPuma Biotechnology, Inc.·Phase 2·NCT00777101·233 enrolled

Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00265733·48 enrolled

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Terminated·AARCAGY/ GINECO GROUP·Phase 2·NCT01069796·64 enrolled

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT05089643·35 enrolled

Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer

Completed·HHoosier Cancer Research Network·Phase 2·NCT00216021·25 enrolled

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07417241·100 enrolled

Capecitabine in Women With Operable Breast Cancer

Terminated·—·Phase 2·NCT00148720·80 enrolled

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04494425·866 enrolled

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Recruiting·FFudan University·Phase 3·NCT06992882·2,306 enrolled

Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer

Unknown status·PPharmatech Oncology·Phase 2·NCT00026442

Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT01891227·40 enrolled

A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00435409·442 enrolled

Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer

Completed·EEmory University·Phase 2·NCT00209092·51 enrolled

Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00005649

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

Recruiting·SSun Yat-sen University·Phase 3·NCT06268652·302 enrolled

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

Terminated·NNational Cancer Centre, Singapore·Phase 2·NCT07166367·3 enrolled

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

Terminated·NNYU Langone Health·Phase 1/2·NCT02297230·44 enrolled

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Completed· Novartis logo

Novartis·Phase 2·NCT01783444·309 enrolled

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

Terminated·SSpanish Breast Cancer Research Group·Phase 2·NCT00130507·14 enrolled

Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

Completed·TTracon Pharmaceuticals Inc.·Phase 1/2·NCT01326481·19 enrolled

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT03204734·132 enrolled

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting·GGBG Forschungs GmbH·Phase 3·NCT04595565·1,332 enrolled

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Completed·RR-Pharm·Phase 3·NCT00080301·752 enrolled

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04681911·71 enrolled

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01939054·90 enrolled

Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00083148·12 enrolled

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Unknown status·—·N/A·NCT06156761·24 enrolled

Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00006108

Gastric Cancer15 trials

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Completed·SSun Yat-sen University·Phase 2·NCT02004769·67 enrolled

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2/3·NCT07332533·490 enrolled

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)

Terminated· Roche logo

Roche·Phase 2·NCT01702558·182 enrolled

Show 12 more trials

Docetaxel and Capecitabine in Advanced Gastric Cancer

Completed·—·Phase 2·NCT00142038·80 enrolled

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05974059·20 enrolled

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

Active, not recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT03257163·40 enrolled

Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer

Terminated·GGruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente·Phase 3·NCT02076594·171 enrolled

Multicentric Randomised Trial for Resectable Gastric Cancer

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02931890·207 enrolled

The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

Completed·FFudan University·Phase 3·NCT02395640·438 enrolled

A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00454636·158 enrolled

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03472365·67 enrolled

Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer

Terminated·DDr Anna Dorothea Wagner·Phase 1/2·NCT01611506·1 enrolled

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03161522·100 enrolled

A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer

Completed·JJeroen Bosch Ziekenhuis·Phase 2·NCT01517009·50 enrolled

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Recruiting·II-Mab Biopharma US Limited·Phase 2·NCT07432295·180 enrolled

Colorectal Cancer12 trials

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04301557·25 enrolled

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06490913·33 enrolled

Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA

Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT05797077·346 enrolled

Show 9 more trials

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06540326·100 enrolled

A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00551213·67 enrolled

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Not yet recruiting·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05720559·100 enrolled

Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Completed·HHerbert Hurwitz, MD·Phase 2·NCT00416494·50 enrolled

Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT01722162·47 enrolled

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Completed·—·Phase 1/2·NCT02861300·50 enrolled

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03563157·2 enrolled

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 1/2·NCT04202978·23 enrolled

Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer

Completed· Roche logo

Roche·Phase 1/2·NCT00345761·64 enrolled

Pancreatic Cancer11 trials

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01821612·23 enrolled

GTX-RT in Borderline Resectable Pancreatic Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01754623·9 enrolled

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Terminated· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT01921751·20 enrolled

Show 8 more trials

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00480584·20 enrolled

Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

Recruiting·EEBG MedAustron GmbH·N/A·NCT04894643·10 enrolled

Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Withdrawn· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 1/2·NCT01017822

Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer

Completed·IIRCCS San Raffaele·Phase 2·NCT01150630·98 enrolled

Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer

Terminated·IIRCCS San Raffaele·Phase 2·NCT01167738·60 enrolled

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00303927·65 enrolled

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen

Completed· Sanofi logo

Sanofi·Phase 3·NCT00417209·408 enrolled

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00372944·70 enrolled

Locally-advanced Rectal Cancer10 trials

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07469306·130 enrolled

Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer

Terminated·UUniversity of Campinas, Brazil·Phase 2·NCT02473094·3 enrolled

Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04663763·40 enrolled

Show 7 more trials

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Unknown status·FFudan University·Phase 2·NCT04411524·50 enrolled

A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Unknown status·FFudan University·Phase 2/3·NCT01064999·240 enrolled

Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

Completed·IInstitute of Oncology Ljubljana··NCT04679597·161 enrolled

Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer

Completed·FFudan University·Phase 2·NCT04518280·130 enrolled

Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer

Completed·UUNICANCER·Phase 3·NCT01804790·461 enrolled

NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer

Unknown status·ZZealand University Hospital·Phase 2·NCT03280407·124 enrolled

Immunotherapy In Locally Advanced Rectal Cancer

Completed·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT03854799·101 enrolled

59 more indications

Metastatic Colorectal Cancer10 trials

Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT02119026·120 enrolled

An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer

Completed· Roche logo

Roche··NCT01664494·563 enrolled

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Terminated·UUniversity of Southern California·Phase 3·NCT03300609·4 enrolled

Show 7 more trials

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT02393755·42 enrolled

Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00230399·15 enrolled

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT03950154·198 enrolled

Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

Completed·BBranimir Sikic·Phase 1·NCT00532909·13 enrolled

Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer

Completed·NNYU Langone Health·Phase 2·NCT00444678·36 enrolled

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT07407465·42 enrolled

An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer

Completed· Roche logo

Roche··NCT01696695·882 enrolled

Capecitabine9 trials

A Confirmation Study of Eribulin in Combination With Capecitabine

Completed· Eisai logo

Eisai·Phase 1/2·NCT01323530·76 enrolled

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07331428·25 enrolled

Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast

Terminated·SStanford University·Phase 1·NCT00473005·18 enrolled

Show 6 more trials

Mono Efficacy of Capecitabine (MoniCa)

Completed·GGBG Forschungs GmbH·Phase 2·NCT00196820·200 enrolled

Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers

Completed·—·Phase 1·NCT00169000·12 enrolled

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated·CChipscreen Biosciences, Ltd.·Phase 2·NCT05336721·9 enrolled

A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT03678649·180 enrolled

Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

Unknown status·PPD Dr. med. Volker Heinemann·Phase 3·NCT00440167·280 enrolled

1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

Completed·UUnidad Integral de Investigación en Oncología S.L.·Phase 2·NCT00345696·32 enrolled

Rectal Cancer4 trials

Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer

Completed·—·Phase 1·NCT04357587·6 enrolled

Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

Recruiting·JJinhua Central Hospital·Phase 2·NCT06204094·37 enrolled

Capecitabine in the Perioperative Treatment of Rectal Cancer

Completed·UUniversitätsmedizin Mannheim·Phase 3·NCT01500993·401 enrolled

Show 1 more trial

IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment

Unknown status·IInstitute of Oncology Ljubljana·Phase 2·NCT02268006·50 enrolled

Biliary Tract Cancer4 trials

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Completed·—·Phase 2·NCT04720131·28 enrolled

Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer

Completed·AASLAN Pharmaceuticals·Phase 2/3·NCT03093870·151 enrolled

Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

Withdrawn·AASLAN Pharmaceuticals·Phase 2·NCT03129074

Show 1 more trial

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06717464·110 enrolled

Adenocarcinoma3 trials

Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction

Completed·TTechnical University of Munich·Phase 2·NCT02287129·75 enrolled

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Unknown status·FFudan University·Phase 2·NCT05111444·65 enrolled

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Unknown status·HHenan Cancer Hospital·Phase 1/2·NCT05608785·45 enrolled

Colon Cancer3 trials

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Suspended·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT05062889·477 enrolled

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

Completed· Roche logo

Roche·Phase 3·NCT00069121·1,886 enrolled

Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery

Unknown status·JJeroen Bosch Ziekenhuis·Phase 2/3·NCT01097265·1,500 enrolled

Hepatocellular Carcinoma3 trials

Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)

Terminated·RRigshospitalet, Denmark·Phase 2·NCT00351195·39 enrolled

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Not yet recruiting·NNanjing Sanhome Pharmaceutical, Co., Ltd.·Phase 2/3·NCT07392866·120 enrolled

Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients

Withdrawn· Sanofi logo

Sanofi·Phase 3·NCT01245582

Esophageal Cancer3 trials

A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer

Completed·CCancer Trials Ireland·Phase 2·NCT01710592·35 enrolled

TaxXel: Taxotere and Xeloda in Esophageal Cancer

Unknown status·KKarolinska University Hospital·Phase 1/2·NCT00821912·93 enrolled

Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00470184·41 enrolled

Cholangiocarcinoma3 trials

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

Completed·—·Phase 2·NCT03079427·101 enrolled

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Terminated·SStanford University·Phase 2·NCT01151761·2 enrolled

Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma

Completed·RRigshospitalet, Denmark·Phase 1/2·NCT00350961·39 enrolled

Nasopharyngeal Carcinoma3 trials

Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

Completed·HHong Kong Nasopharyngeal Cancer Study Group Limited·Phase 3·NCT00379262·803 enrolled

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Not yet recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 3·NCT05717764·500 enrolled

Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT02958111·406 enrolled

Patients With Locally Advanced Rectal Cancer2 trials

Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00766155·1,094 enrolled

External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer

Completed·SSwiss Cancer Institute·Phase 1/2·NCT00869570·54 enrolled

Patients With Advanced Solid Tumors2 trials

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00006465·22 enrolled

A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT05344742·116 enrolled

Neoadjuvant Treatment2 trials

Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment

Completed·PPeking University Cancer Hospital & Institute··NCT02860234·68 enrolled

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Recruiting·—·Phase 2·NCT05815303·92 enrolled

Triple-Negative Breast Cancer2 trials

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Active, not recruiting·SShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.·Phase 3·NCT06519370·350 enrolled

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05374512·644 enrolled

Rectal Adenocarcinoma2 trials

Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00625183·5 enrolled

A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma

Completed·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT01634685·15 enrolled

Radiation Therapy2 trials

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

Completed·UUNC Lineberger Comprehensive Cancer Center··NCT00280761·47 enrolled

Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer

Unknown status·AAUSL Romagna Rimini·Phase 2·NCT04083365·100 enrolled

Locally Advanced2 trials

Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.

Unknown status·PPeking Union Medical College Hospital·N/A·NCT03042000·1,200 enrolled

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Completed· Amgen logo

Amgen·Phase 1/2·NCT00719550·130 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 3·NCT02548195·286 enrolled

mCRC1 trial

Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC

Unknown status·LLudwig-Maximilians - University of Munich·Phase 3·NCT01249638·516 enrolled

Cardiovascular1 trial

Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine

Completed·UUniversity of Edinburgh·Phase 2·NCT01845337·59 enrolled

Cervical Cancer1 trial

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

Completed·UUniversity of California, Irvine·Phase 2·NCT00257348·5 enrolled

Metastatic Biliary Tract Carcinoma1 trial

Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Not yet recruiting·BBa Yi·Phase 2·NCT06430827·20 enrolled

Second-line Treatment1 trial

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

Unknown status·—··NCT06169202·50 enrolled

Small Bowel Cancer1 trial

Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019773

Advanced Malignancy1 trial

Everolimus and Capecitabine in Patients With Advanced Malignancy

Unknown status·—·Phase 1/2·NCT01079702·35 enrolled

Liver Metastases1 trial

Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases

Unknown status·AArbeitsgruppe Lebermetastasen und Tumoren·Phase 3·NCT00156975·384 enrolled

Unresectable Solid Tumor1 trial

Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00074321·84 enrolled

Pancreatic Carcinoma1 trial

A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma

Completed·YYale University·Phase 1/2·NCT00411762·25 enrolled

Intraperitoneal1 trial

Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT03792269·100 enrolled

First-line Treatment1 trial

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT05799820·60 enrolled

Stage III Rectal Cancer1 trial

Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer

Completed·UUNICANCER·Phase 3·NCT00227747·598 enrolled

Liver Cancer1 trial

Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

Recruiting·CCenter Eugene Marquis·Phase 2·NCT05265208·62 enrolled

Efficacy and Safety1 trial

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University··NCT06504901·30 enrolled

Gastric Carcinoma1 trial

Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma

Completed·Xxie congying·Phase 2·NCT01711242·208 enrolled

Esophageal Adenocarcinoma1 trial

The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04065282·36 enrolled

Nasopharyngeal Cancer1 trial

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06892431·150 enrolled

HER2 Positive1 trial

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Terminated·SSilverback Therapeutics·Phase 1/2·NCT05091528·2 enrolled

Combination Therapy1 trial

A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02359058·18 enrolled

Fallopian Tube Cancer1 trial

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Terminated·WWake Forest University Health Sciences·Phase 2·NCT00354601·2 enrolled

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169790

Metastatic Cancer1 trial

A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Completed· Roche logo

Roche·Phase 2·NCT01131078·306 enrolled

Gastric/Gastroesophageal Junction Cancer1 trial

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Terminated·AAHS Cancer Control Alberta·Phase 1/2·NCT00130936·50 enrolled

Chemotherapy1 trial

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06788171·35 enrolled

Maintenance Treatment1 trial

Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC

Unknown status·RRuijin Hospital·Phase 2/3·NCT02893540·250 enrolled

Postoperative Adjuvant Therapy1 trial

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06685289·70 enrolled

Metastatic Neuroendocrine Tumor1 trial

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

Completed·—·Phase 2·NCT00602082·84 enrolled

Pancreatic Adenocarcinoma1 trial

Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Terminated·WWashington University School of Medicine·Phase 1/2·NCT02352831·16 enrolled

Gastric Adenocarcinoma1 trial

Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Completed·NNovoCure GmbH·N/A·NCT04281576·28 enrolled

Adjuvant Treatment1 trial

A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer

Completed· Roche logo

Roche·Phase 4·NCT02581423·63 enrolled

Hypofractionated Radiotherapy1 trial

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT06928584·221 enrolled

Stage III Colon Cancer1 trial

An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer

Completed· Roche logo

Roche··NCT01442155·74 enrolled

Organ Preservation1 trial

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University··NCT06504875·23 enrolled

Stomach Cancer1 trial

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02872116·2,031 enrolled

Carcinoma of Unknown Primary1 trial

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193609·48 enrolled

Breast1 trial

Chemotherapeutic Agents in Brain/Breast

Completed·—··NCT00795678·10 enrolled

Primary Peritoneal Cavity Cancer1 trial

Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Terminated·GGynecologic Oncology Group·Phase 2·NCT00006812

Unspecified1 trial

Detect V / CHEVENDO (Chemo vs. Endo)

Active, not recruiting·PProf. Wolfgang Janni·Phase 3·NCT02344472·271 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 30, 1998

XELODA

NDA NDA020896

Apr 30, 1998

XELODA

NDA NDA020896

Feb 4, 1999

XELODA

NDA NDA020896

Feb 4, 1999

XELODA

NDA NDA020896

Apr 2, 1999

XELODA

NDA NDA020896

Aug 17, 1999

XELODA

NDA NDA020896

Mar 24, 2000

XELODA

NDA NDA020896

Apr 30, 2001

XELODA

NDA NDA020896

Apr 30, 2001

XELODA

NDA NDA020896

Sep 7, 2001

XELODA

NDA NDA020896

Sep 7, 2001

XELODA

NDA NDA020896

Mar 15, 2003

XELODA

NDA NDA020896

Jun 15, 2005

XELODA

NDA NDA020896

Feb 5, 2011

XELODA

NDA NDA020896

Dec 10, 2013

XELODA

NDA NDA020896

Jul 22, 2014

XELODA

NDA NDA020896

Oct 16, 2014

XELODA

NDA NDA020896

Jan 5, 2015

XELODA

NDA NDA020896

Mar 2, 2015

XELODA

NDA NDA020896

Mar 20, 2015

XELODA

NDA NDA020896

Dec 22, 2015

XELODA

NDA NDA020896

Dec 14, 2016

XELODA

NDA NDA020896

Feb 22, 2019

XELODA

NDA NDA020896

May 19, 2021

XELODA

NDA NDA020896

Dec 14, 2022

XELODA

NDA NDA020896

Dec 14, 2022

XELODA

NDA NDA020896

Dec 14, 2022

XELODA

NDA NDA020896

Dec 14, 2022

XELODA

NDA NDA020896

Dec 14, 2022

XELODA

NDA NDA020896

Dec 14, 2022

XELODA

NDA NDA020896

Dec 14, 2022

XELODA

NDA NDA020896

Dec 14, 2022

XELODA

NDA NDA020896

Oct 3, 2025

XELODA

NDA NDA020896

Sources

References

[1]
ClinicalTrials.gov — 1353 trial records for Capecitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Xeloda drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Capecitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Capecitabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020896). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Engelhard Arzneimittel GmbH & Co.KG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Thymidylate Synthase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: EEngelhard Arzneimittel GmbH & Co.KG

Xeloda

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Breast Cancer51 trials

Gastric Cancer15 trials

Colorectal Cancer12 trials

Pancreatic Cancer11 trials

Locally-advanced Rectal Cancer10 trials

Metastatic Colorectal Cancer10 trials

Capecitabine9 trials

Rectal Cancer4 trials

Biliary Tract Cancer4 trials

Adenocarcinoma3 trials

Colon Cancer3 trials

Hepatocellular Carcinoma3 trials

Esophageal Cancer3 trials

Cholangiocarcinoma3 trials

Nasopharyngeal Carcinoma3 trials

Patients With Locally Advanced Rectal Cancer2 trials

Patients With Advanced Solid Tumors2 trials

Neoadjuvant Treatment2 trials

Triple-Negative Breast Cancer2 trials

Rectal Adenocarcinoma2 trials

Radiation Therapy2 trials

Locally Advanced2 trials

Intrahepatic Cholangiocarcinoma1 trial

mCRC1 trial

Cardiovascular1 trial

Cervical Cancer1 trial

Metastatic Biliary Tract Carcinoma1 trial

Second-line Treatment1 trial

Small Bowel Cancer1 trial

Advanced Malignancy1 trial

Liver Metastases1 trial

Unresectable Solid Tumor1 trial

Pancreatic Carcinoma1 trial

Intraperitoneal1 trial

First-line Treatment1 trial

Stage III Rectal Cancer1 trial

Liver Cancer1 trial

Efficacy and Safety1 trial

Gastric Carcinoma1 trial

Esophageal Adenocarcinoma1 trial

Nasopharyngeal Cancer1 trial

HER2 Positive1 trial

Combination Therapy1 trial

Fallopian Tube Cancer1 trial

Cancer of Unknown Primary1 trial

Total Neoadjuvant Therapy1 trial

Lymphoma1 trial

Metastatic Cancer1 trial

Gastric/Gastroesophageal Junction Cancer1 trial

Chemotherapy1 trial

Maintenance Treatment1 trial

Postoperative Adjuvant Therapy1 trial

Metastatic Neuroendocrine Tumor1 trial

Pancreatic Adenocarcinoma1 trial

Gastric Adenocarcinoma1 trial

Adjuvant Treatment1 trial

Hypofractionated Radiotherapy1 trial

Stage III Colon Cancer1 trial

Organ Preservation1 trial

Stomach Cancer1 trial

Carcinoma of Unknown Primary1 trial

Breast1 trial

Primary Peritoneal Cavity Cancer1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News